EICHOR
● Recruiting
A Phase I/IIa Study of SYS6041 in Patients With Advanced Solid Tumors
Condition: Advanced Solid Tumors · Sponsor: CSPC Megalith Biopharmaceutical Co.,Ltd.
About this study
This trial is the first-in-human study of SYS6041, a multicenter, open-label, dose-escalation, dose-reassignment and cohort-expansion Phase I/IIa clinical study, which aims to evaluate the safety, tolerability, pharmacokinetic (PK) profile and preliminary antitumor efficacy of SYS6041 in participants with advanced solid tumors.
This description comes directly from the study's public registry record.
Talk to the study team
Clinical Trials Information Group officer · 031169085587 · ctr-contact@cspc.cn
Always discuss trial participation with your own doctor first.
Locations (1)
| Xiaohua | Shanghai, Shanghai Municipality, China | Recruiting |
Sponsor or site team? See the site landscape for this trial — listed sites, countries, and recruiting-density context.
Follow this study
Save your interest here for when the public record changes — results posted, or the study's status changes. Email alerts for this study aren't switched on yet.
We keep this only about this public record, and never email you without alerts being switched on. Want it removed at any time? Email hello@eichor.com. Never medical advice. By subscribing you agree to our Terms of Use and Privacy Policy.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT07744763